AML Hub

Key questions in FLT3-mutated AML, and ongoing research to address these

5:15

The AML Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What are the key ongoing questions in FLT3-mutated AML, and how are ongoing trials addressing these?

Craddock begins by highlighting the progress made in the treatment of FLT3-mutated (FLT3m) acute myeloid leukemia (AML) over the past decade with two large randomized clinical…